Table II.
Details regarding allergologic evaluation and vaccination
| Evaluation and vaccination | Value |
|---|---|
| Skin testing∗ | 17/69 |
| Polysorbate 80 positive | 1/7 |
| Polysorbate 80 negative | 6/7 |
| Macrogol negative | 12/12 |
| Tromethamine negative | 1/1 |
| Administered vaccine (n = 69) | |
| Comirnaty | 57 |
| Jcovden | 9 |
| Vaxzevria | 3 |
| Symptoms immediately after vaccination | 2/69 |
| Anaphylaxis (dyspnea, urticaria) | 1/2 |
| Urticaria | 1/2 |
| Symptoms after administration of placebo, n (%) | 19/69 |
| Subjective feeling of pharyngeal swelling | 4 (21) |
| Generalized malaise | 4 (21) |
| Headache | 3 (15) |
| Pruritus | 3 (15) |
| Thoracal pain | 3 (15) |
| Nausea | 4 (21) |
| Syncope | 1 (5) |
| Palpitations | 4 (21) |
| Symptoms after placebo per referral group | |
| Anxiety | 4/23 |
| Symptoms after first or second dose | 14/41 |
| Potential severe symptoms during index reaction | 6/14 |
| Multiple anaphylaxis | 0/1 |
| Refused by vaccination center | 1/4 |
∗
Only in patients who showed signs and symptoms compatible with an immediate hypersensitivity reaction within 1 hour of administration of the vaccine.